

# Curriculum Vitae

Last updated: 15 Jun 2022

Hajeong Lee, MD, PhD

Seoul National University Hospital, Department of Internal Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03080, KOREA, REPUBLIC OF

**Office** 82-2-2072-4905

**E-mail** mdhjlee@gmail.com

## Educational background

Seoul National University College of Medicine, Bachelor

Seoul National University College of Medicine, Immunology, Master

Seoul National University College of Medicine, Immunology, Doctor

## Training

Rotating Internship, Seoul National University Hospital (SNUH)

Residency, Department of Internal Medicine, SNUH

Fellowship, Division of Nephrology, Department of Internal Medicine, SNUH

Researcher, Seoul National University, Biomedical Research Institute, SNUH

## Academic position

Assistant Professor, Division of Nephrology, Department of Internal Medicine, SNUH (2013-2020)

Associate Professor, Division of Nephrology, Department of Internal Medicine, SNUH since 2020

## Licensure

Medical Doctor from the Ministry of Health and Welfare (License No. 86145)

Korean Board of Internal Medicine from the Ministry of Health and Welfare (License No. 12563)

Korean Board of Nephrology from the Ministry of Health and Welfare (License No. 5-12-638)

Certified Physicians in BioMedical Informatics from the Korean Society of Medical Informatics (KOSMI) (License No. CPBMI018)

## Professional Membership

Korean Society of Internal Medicine

Korean Society of Nephrology

Korean Society of Transplantation

International Society of Nephrology  
American Society of Nephrology  
American Society of Transplantation  
The Transplantation Society

### **Advisory Board/Committee Membership**

Member, Institutional Review Board, SNUH (2016-)  
Secretary, Kidney Research Institute, SNU (2018-2020)  
Advisory board member for glomerulonephritis, Committee on Scientific Programs, KSN (2018-)  
Advisory board member for transplantation, Committee on Scientific Programs, KSN (2021-)  
Member, ASN Kidney News Editorial Board (2021-)

### **Awards**

Cum Laude – Seoul National University College of Medicine, 2005  
Excellent Resident Award – Seoul National University Hospital, 2009  
Top oral abstract (as a PI) – American Society of Nephrology, Kidney week 2016  
Young Investigator Award – Korean Society of Nephrology, 2019  
Best abstract award (as a PI) – Asian Transplantation Week, 2019  
Best abstract award (as a PI) – Asian Transplantation Week, 2020  
Best abstract award (as a PI) – Korean Society of Nephrology, 2020  
Best abstract award (as a PI) – Asian Transplantation Week, 2021  
Best abstract award (as a PI) – Korean Society of Nephrology, 2022  
Best Academic Award – Korean Society of Nephrology, 2022  
Academic Award (명주완상) – Seoul National University Hospital, 2022

### **Clinical Trial Experience, as a center principal investigator**

1. An adaptive seamless randomized, double-blind, placebo-controlled, dose-ranging study to investigate the efficacy and safety of LNP023 in primary IgA nephropathy patients, Novartis, 2019-2021
2. A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN). Omeros, 2020- : as a National Leader
3. A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients, Vitaeris, 2020-
4. A multi-center, randomized, double-blind, placebo-controlled, parallel group, phase III study to evaluate the efficacy and safety of LNP023 in primary IgA nephropathy patients, Novartis, 2021-

5. A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants Who Have Thrombotic Microangiopathy Associated with a Trigger, Alexion, 2021-04-21
6. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of KBP-5074, a Mineralocorticoid Receptor Antagonist, in Subjects with Uncontrolled Hypertension Who Have Moderate or Severe (Stage 3b/4) Chronic Kidney Disease, 2021-
7. A multicenter, single-arm, open-label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult aHUS patients who are naive to complement inhibitor therapy, 2021-
8. A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN), 2021-

### **Government funding, as a principal investigator**

1. STAT pathway activation and the interaction of its regulatory proteins in the pathogenesis of glomerulonephritis, Ministry of Health and Welfare of Korea (May 2011~Apr 2012)
2. Search for the role and mechanism of VEGF as a new biomarker for chronic kidney disease, National Research Foundation of Korea (May 2014 ~ Apr 2017)
3. A systems approach to discover a novel transcriptomic signature for IgA nephropathy, Ministry of Health and Welfare of Korea (Nov 2015 ~ Oct 2018)
4. Guidelines for providing customized health care services for kidney transplant recipients and donors, Ministry of Health and Welfare of Korea (Sep 2018 ~ Apr 2021)
5. Health Policy and Management for Safety of Living Kidney Donors. National Evidence-based Healthcare Collaborating Agency (Jan 2019 ~ Dec 2020)
6. Mucosal immune modulation and glomerular inflammation in IgA nephropathy, National Research Foundation of Korea (Mar 2019 ~ Feb 2022)
7. High-quality, multi-modal synthetic medical data generation technology development for predicting morbid postoperative complications, Ministry of Health and Welfare of Korea (Jun 2021 ~ Dec 2023)
8. Discovery of metagenomic signature for chronic kidney disease implying disease-specific pathogenesis, National Research Foundation of Korea (Mar 2022 ~ Feb 2025)

### **Guest lecture for International Scholastic Society Meeting**

1. Simple Assessment of Postoperative AKI Risk (SPARK) Classification before Noncardiac Surgery, APSN AKI CRRT Parallel Track (Regional Topics) (Oct 2019)
2. Community-acquired AKI in the Asian Pacific Region, APSN AKI CRRT Parallel Track (Regional Topics) (Oct 2019)
3. Machine Learning Approach in Predicting the Outcome of IgA Nephropathy, APCN

2020 Advances in IgA Nephropathy (Oct 2020)

4. Role of AKI Risk Scores, APCN 2021 Acute Kidney Injury: Diagnostic and Prognostic Tools (Aug 2021)

5. Korean Glomerular Disease Cohorts: Current Status and Future Direction, HKSJN – KSN Joint Symposium (Sep 2021)

## Patents

1. Predicting system and method of postoperative acute kidney injury risk after non-cardiac major surgery (10-2019-0139378): Korea and USA
2. Electronic device for predicting side effects of joint replacement surgery based on pre-operative data and operation method thereof (10-2020-0119455): Korea

## Recent publications (2017-2022)

A total of 146 SCI/SCIE articles including 43 as a first or corresponding author

### 1. IgA nephropathy

RNA-seq profiling of tubulointerstitial tissue reveals a potential therapeutic role of dual anti-phosphatase 1 in glomerulonephritis. Park S, **Lee H**, Lee J, Lee S, Cho S, Huh H, Kim JY, Park M, Lee S, Kim Y, Choi M, Joo KW, Kim YS, Yang SH, Kim DK. *J Cell Mol Med*. 2022 Jun;26(12):3364-3377

RNA-Seq profiling of microdissected glomeruli identifies potential biomarkers for human IgA nephropathy. Park S, Yang SH, Jeong CW, Moon KC, Kim DK, Joo KW, Kim YS, Lee JW, **Lee H**. *Am J Physiol Renal Physiol*. 2020 Nov 1;319(5):F809-F821

Comparative analysis of the tonsillar microbiota in IgA nephropathy and other glomerular diseases. Park JI, Kim TY, Oh B, Cho H, Kim JE, Yoo SH, Lee JP, Kim YS, Chun J, Kim BS, **Lee H**. *Sci Rep*. 2020 Oct 1;10(1):16206.

The Association between Gut Microbiota and Uremia of Chronic Kidney Disease. Kim JE, Kim HE, Park JI, Cho H, Kwak MJ, Kim BY, Yang SH, Lee JP, Kim DK, Joo KW, Kim YS, Kim BS, **Lee H**. *Microorganisms*. 2020 Jun 16;8(6):907.

Clinical importance of the updated Oxford classification in allograft IgA nephropathy. Park S, Go H, Baek CH, Kim YH, Kim YC, Yang SH, Lee JP, Min SI, Ha J, Song EY, Kim YS, Park SK, **Lee H**, Moon KC. *Am J Transplant*. 2019 Oct;19(10):2855-2864.

Glomerular crescents are associated with worse graft outcome in allograft IgA nephropathy. Park S, Baek CH, Cho H, Yu MY, Kim YC, Go H, Kim YH, Lee JP, Min SI, Ha J, Moon KC, Kim YS, Ahn C, Park SK, **Lee H**. *Am J Transplant*. 2019 Jan;19(1):145-155.

Pregnancy in women with immunoglobulin A nephropathy: are obstetrical complications associated with renal prognosis? Park S, Yoo KD, Park JS, Hong JS, Baek S, Park SK, Chin HJ, Na KY, Choi Y, Kim DK, Oh KH, Joo KW, Kim YS, **Lee H**. *Nephrol Dial Transplant*. 2018 Mar 1;33(3):459-465.

### 2. Kidney Transplantation

Clinical Significances of Anti-Collagen Type I and Type III Antibodies in Antibody-Mediated Rejection. Park S, Yang SH, Kim J, Cho S, Yang J, Min SI, Ha J, Jeong CW, Bhoo SH, Kim YC, Kim DK, Oh KH, Joo KW, Kim YS, Moon KC, Song EY, **Lee H**. *Transpl Int*. 2022 May 11;35:10099.

De novo major cardiovascular events in kidney transplant recipients: a comparative matched cohort study. Kim JE, Park J, Park S, Yu MY, Baek SH, Park SH, Han K, Kim YC, Kim DK, Oh KH, Joo KW, Kim YS, **Lee H**. *Nephrol Dial Transplant*. 2022 Apr 9;gfac144

Risk of active tuberculosis infection in kidney transplantation recipients: A matched comparative nationwide cohort study. Park S, Park S, Kim JE, Yu MY, Kim YC, Kim DK, Joo KW, Kim YS, Han K, **Lee H**. *Am J Transplant*. 2021 Nov;21(11):3629-3639

Association between early post-transplant hypertension or related antihypertensive use and prognosis of kidney transplant recipients: a nationwide observational study. Park S, Kang SJ, Lee JW, Kim JE, Kim Y, Kim K, Park M, Kim YC, Kim YS, Lim Y, **Lee H**. *J Nephrol*. 2021 Oct;34(5):1457-1465.

Socioeconomic dependency and kidney transplantation accessibility and outcomes: a nationwide observational cohort study in South Korea. Park S, Park J, Kim M, Kim JE, Yu MY, Kim K, Park M, Kim YC, Kim DK, Joo KW, Kim YS, **Lee H**. *J Nephrol*. 2021 Feb;34(1):211-219.

Disparity in Accessibility to and Prognosis of Kidney Transplantation According to Economic Inequality in South Korea: A Widening Gap After Expansion of Insurance Coverage. Park S, Park GC, Park J, Kim JE, Yu MY, Kim K, Park M, Kim YC, Kim DK, Joo KW, Kim YS, **Lee H**. *Transplantation*. 2021 Feb 1;105(2):404-412.

Characteristics of kidney transplantation recipients over time in South Korea. Park S, Kim M, Kim JE, Kim K, Park M, Kim YC, Joo KW, Kim YS, **Lee H**. *Korean J Intern Med*. 2020 Nov;35(6):1457-1467.

Effect of the similarity of gut microbiota composition between donor and recipient on graft function after living donor kidney transplantation. Kim JE, Kim HE, Cho H, Park JI, Kwak MJ, Kim BY, Yang SH, Lee JP, Kim DK, Joo KW, Kim YS, Kim BS, **Lee H**. *Sci Rep*. 2020 Nov 3;10(1):18881

Economic Impact of Donating a Kidney on Living Donors: A Korean Cohort Study. Park S, Park J, Kang E, Lee JW, Kim Y, Park M, Kim K, Kim HJ, Han M, Cho JH, Lee JP, Lee S, Kim SW, Park SM, Chae DW, Chin HJ, Kim YC, Kim YS, Choi I, **Lee H**. *Am J Kidney Dis*. 2022 Feb;79(2):175-184.e1

Long-term Mortality Risks Among Living Kidney Donors in Korea. Kim Y, Yu MY, Yoo KD, Jeong CW, Kim HH, Min SI, Ha J, Choi Y, Ko AR, Yun JM, Park SM, Yang SH, Kim DK, Oh KH, Joo KW, Ahn C, Kim YS, **Lee H**. *Am J Kidney Dis*. 2020 Jun;75(6):919-925.

Metabolic risks in living kidney donors in South Korea. Kang E, Park J, Kim HJ, Park S, Park M, Kim Y, Kim K, Park SM, Chae DW, Chin HJ, Lee JP, Lee S, Kim SW, Cho JH, Han M, Kim YC, Kim YS, Choi I, **Lee H**. *Kidney Res Clin Pract*. 2021 Dec;40(4):645-659.

*I hereby declare that the above statement is true and correct in every respect to the best of my knowledge*

*Hajeong Lee, MD., PhD.* 